Key Clinical Messages: Behçet's disease (BD) or syndrome is a chronic, recurrent, multisystem, inflammatory vasculitis disorder with findings of oral aphthous ulcers, genital ulcers, and uveitis. Gastrointestinal (GI) involvement can be the initial presentation as presented in this case.
Abstract: Behçet's disease (BD) or syndrome is a chronic, recurrent, multisystem, inflammatory vasculitis disorder of unknown etiology with classical findings of oral aphthous ulcers, genital ulcers, and ocular involvements including chronic anterior, intermediate, posterior, and even panuveitis. Gastrointestinal involvement in BD usually presents with chronic diarrhea, hematochezia as the disease affects ileocecal area which might be similar to presentation of inflammatory bowel diseases. Here, we report a case of undiagnosed BD who presented with chronic diarrhea for 4 months, leading to the diagnosis of BD and responded well to corticosteroid therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196402 | PMC |
| http://dx.doi.org/10.1002/ccr3.7359 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Am J Hematol
January 2025
Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 10/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017-004012-19).
View Article and Find Full Text PDFNature and prevalence of long-term conditions in people with intellectual disability: retrospective longitudinal population-based study.
BMJ Open
January 2025
Leicestershire Partnership NHS Trust, Leicester, UK.
Objective: Explore the nature and prevalence of long-term conditions in individuals with intellectual disability.
Design: Retrospective longitudinal population-based study.
Setting: Primary and secondary care data across the population of Wales with the Secure Anonymised Information Linkage (SAIL) Databank.
Intestinal histoplasmosis with granulomatous colonic and mesenteric lymphadenitis due to Histoplasma mississippiense infection in an American Mammoth Jackstock donkey (Equus asinus).
J Comp Pathol
January 2025
Department of Pathobiology and Population Medicine, Mississippi State University, 240 Wise Center Drive, Mississippi State, Mississippi 39762, USA.
Histoplasmosis is a rarely reported clinical disease of equids in North America and is historically attributed to Histoplasma capsulatum var. capsulatum. This report details a case of intestinal histoplasmosis with lymphadenitis in an American Mammoth Jackstock donkey from Mississippi.
View Article and Find Full Text PDFTowards routine high-throughput analysis of fecal bile acids: validation of an enzymatic cycling method for the quantification of total bile acids in human stool samples on fully automated clinical chemistry analyzers.
Clin Chem Lab Med
January 2025
Institute for Biomolecular Research, Hochschulen Fresenius gemeinnützige Trägergesellschaft mbH, University of Applied Sciences, Idstein, Germany.
Objectives: Bile acid diarrhea is a common but underdiagnosed condition. Because the gold standard test (SeHCAT) is time-consuming and not widely available, fecal bile acid excretion is typically assessed by chromatography and mass spectrometry. Although enzymatic cycling assays are well established for the rapid and cost-effective analysis of total bile acids (TBA) in serum or plasma, their full potential has yet not been extended to stool samples in clinical routine.
View Article and Find Full Text PDFEfficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis.
BMC Psychiatry
January 2025
Department of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
Background: The study aimed to comprehensively analyze and establish a framework for evaluating the efficacy of microbiome-targeted treatment (MTT) for depression.
Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and the Chinese National Knowledge Infrastructure database for randomized controlled trials (RCTs) on MTT in treating depression until October 19, 2023. A meta-analysis was conducted to evaluate the efficacy and safety of MTT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!